Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of CML patients achieving deep and sustained molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Loscocco, Federica, Visani, Giuseppe, Ruzzo, Annamaria, Bagaloni, Irene, Fuligni, Fabio, Galimberti, Sara, Di Paolo, Antonello, Stagno, Fabio, Pregno, Patrizia, Annunziata, Mario, Gozzini, Antonella, Barulli, Sara, Gabucci, Elisa, Magnani, Mauro, Isidori, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155509/
https://www.ncbi.nlm.nih.gov/pubmed/34055641
http://dx.doi.org/10.3389/fonc.2021.672287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155509/
https://www.ncbi.nlm.nih.gov/pubmed/34055641
http://dx.doi.org/10.3389/fonc.2021.672287

Ejemplares similares